clinical trial · NCT05873205
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Blood CancerRefractory Immune CytopeniasIsatuximab
brief summary
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
started
Jul 21, 2023
primary completion
Jun 29, 2027
completion
Jun 29, 2027
last updated
Apr 2, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol